相关实验视频
Updated: May 14, 2025
10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
9.4K
耐火性Mycobacterium avium复杂肺部疾病 (IMPULSE-7) 的重组互白素-7治疗:一个试点II期,单中心,随机化,临床试验
Carlos Mejia-Chew1, Andrej Spec2, Andrew H Walton3
1Infectious Diseases, Washington University School of Medicine, 4523 Clayton Ave., Campus Box 8051, St. Louis, MO 63110-0193, USA.
Therapeutic advances in infectious disease
|May 12, 2025
概括
介质素7 (IL-7) 没有治愈耐火性Mycobacterium avium复杂肺病 (MAC-LD),未能转化菌培养物. 然而,IL-7确实成功逆转了淋巴缺血症,并在患有MAC-LD的患者中增加了淋巴细胞数量.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
背景情况:
- 非结核菌 (NTM) 疾病,特别是Mycobacterium avium复杂肺病 (MAC-LD),是具有挑战性的机会性感染,通常耐治疗.
- 国际白素7 (IL-7),一种已知的增强免疫力的细胞因子,已在体外显示出增强Mycobacterium avium的巨杀死潜力.
研究的目的:
- 为了评估Interleukin 7 (IL-7) 在被诊断为耐火性MAC-LD的患者中的疗效.
- 通过单细胞RNA测序 (scRNA-seq) 探索MAC-LD潜在免疫抑制的基础分子机制.
主要方法:
- 进行了一项前性,单中心的随机研究,涉及耐火性MAC-LD的患者.
- 参与者接受了两组每周四次IL-7注射,根据肺腔的存在分层. 主要终点是液培养转化为半年内阴性.
主要成果:
- 在8名参与者中,有6人完成了IL-7治疗方案. 所有完成者都表现出绝对淋巴细胞计数 (ALC) 的增加,但没有一个人在六个月内实现了唾液培养转化.
- 与基线相比,在二次结果中没有观察到显著差异. IL-7耐受性良好,两名参与者在唾液培养物中对MAC的时间阳性增加.
- 单细胞RNA测序 (scRNA-seq) 数据表明与免疫抑制途径相关的基因的上调.
结论:
- 干白素7 (IL-7) 治疗并没有导致长培养转换在耐火MAC-LD的成年人.
- 在这些患者中,IL-7有效地逆转了淋巴缺血,并维持了ALC的增加.
- 虽然可以考虑使用新型抗微生物药物进行更长的IL-7疗程,但结构性肺病似乎是实现治愈的更重要因素,而不是免疫状态.
更多相关视频
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.7K
10:03Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
9.7K
相关概念视频
01:27Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406
01:24T Cell Types and Functions
638
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
638